All In Biotech

Drug Trial Radar · NCT06194825

EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid Cardiomyopathy

A Phase 3, Randomized Study, With Initial 24-week, Double-Blind and Placebo-Controlled Treatment Phase, Followed by An 80-week Open-label Extension Treatment Phase to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-Term Safety in Chinese Participants With Transthyretin Amyloid Cardiomyopathy (EPIC-ATTR)

Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

64

Actual

Start

Dec 1, 2023

Primary completion

May 13, 2026

Study completion Jan 5, 2027

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jan 8, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 20 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to investigate the effect of eplontersen compared to placebo on the reduction of serum TTR concentration and long-term safety in Chinese participants with hereditary or wild-type transthyretin amyloid cardiomyopathy.

Conditions

  • Transthyretin Amyloid Cardiomyopathy

Interventions

  • EplontersenDrug

    Eplontersen by subcutaneous injection

  • PlaceboDrug

    Eplontersen-matching placebo by subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change of serum TTR concentration from baselineTime frame: up to 24 weeks

Locations

26 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Beijing, China

  • Research Site

    Beijing, China

  • Research Site

    Beijing, China

  • Research Site

    Beijing, China

  • Research Site

    Beijing, China

  • Research Site

    Changsha, China

  • Research Site

    Changsha, China

  • Research Site

    Changsha, China

  • Research Site

    Chengdu, China

  • Research Site

    Chengdu, China

  • Research Site

    Chongqing, China

  • Research Site

    Chongqing, China

  • Research Site

    Guangzhou, China

  • Research Site

    Guangzhou, China

  • Research Site

    Ha’erbin, China

  • Research Site

    Hangzhou, China

  • Research Site

    Hangzhou, China

  • Research Site

    Hangzhou, China

  • Research Site

    Jinan, China

  • Research Site

    Nanchang, China

  • Research Site

    Shanghai, China

  • Research Site

    Suzhou, China

  • Research Site

    Taiyuan, China

  • Research Site

    Wuhan, China

  • Research Site

    Wuhan, China

  • Research Site

    Xi'an, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.